GdCl3 reduces hyperglycaemia through Akt/FoxO1-induced suppression of hepatic gluconeogenesis in type 2 diabetic mice

Clinical Science

Volumn 127, Issue 2, 2014, Pages 91-100

  Wang, Qian ^a   Wang, Ning ^a   Dong, Mei ^a   Chen, Fang ^a   Li, Zhong ^a   Chen, Yuanyuan ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Gluconeogenesis; Glucose 6 phosphatase (G6pase); Insulin resistance; Phosphoenolpyruvate carboxykinase (Pepck); Type 2 diabetes

Indexed keywords

GADOLINIUM CHLORIDE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; HUMAN INSULIN; INSULIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROTEIN KINASE B; PYRUVIC ACID; TRANSCRIPTION FACTOR FKHR; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, MOUSE; GADOLINIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEPATIC GLUCONEOGENESIS; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID DIET; LIVER CELL CARCINOMA; LIVER METABOLISM; LONG TERM CARE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG EFFECT; LIVER; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; BLOOD GLUCOSE; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; FORKHEAD TRANSCRIPTION FACTORS; GADOLINIUM; GLUCONEOGENESIS; GLUCOSE; GLUCOSE-6-PHOSPHATASE; HYPERGLYCEMIA; LIVER; MALE; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84897509634     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20130670     Document Type: Article

References (31)

1. Zimmet P. (1982) Type 2 (non-insulin-dependent) diabetes-an epidemiological overview. Diabetologia 22, 399-411.
2. American Diabetes Association (2009) Standards of medical care in diabetes-2009. Diabetes Care 32 (Suppl. 1), S13-S61.
3. Magnusson I., Rothman D. L., Katz L. D., Shulman R. G. and Shulman G. I. (1992) Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J. Clin. Invest. 90, 1323-1327.
4. Gastaldelli A., Toschi E., Pettiti M., Frascerra S., Quinones-Galvan A., Sironi A. M., Natali A. and Ferrannini E. (2001) Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. Diabetes 50, 1807-1812.
5. Rossetti L., Giaccari A., Barzilai N., Howard K., Sebel G. and Hu M. (1993) Mechanism by which hyperglycemia inhibits hepatic glucose production in conscious rats. Implications for the pathophysiology of fasting hyperglycemia in diabetes. J. Clin. Invest. 92, 1126-1134.
6. Saltiel A. R. (2001) New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104, 517-529.
7. Schenk S., Saberi M. and Olefsky J. M. (2008) Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Invest. 118, 2992-3002.
8. Biggs, III, W. H., Meisenhelder J., Hunter T., Cavenee W. K. and Arden K. C. (1999) Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc. Natl. Acad. Sci. U.S.A. 96, 7421-7426.
9. Durham S. K., Suwanichkul A., Scheimann A. O., Yee D., Jackson J. G., Barr F. G. and Powell D. R. (1999) FKHR binds the insulin response element in the insulin-like growth factor binding protein-1 promoter. Endocrinology 140, 3140-3146.
10. Nakae J., Biggs, III, W. H., Kitamura T., Cavenee W. K., Wright C. V., Arden K. C. and Accili D. (2002) Regulation of insulin action and pancreatic β-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat. Genet. 32, 245-253.
11. Samuel V. T., Choi C. S., Phillips T. G., Romanelli A. J., Geisler J. G., Bhanot S., McKay R., Monia B., Shutter J. R., Lindberg R. A. et al. (2006) Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 55, 2042-2050.
12. Cui X. B., Wang C., Li L., Fan D., Zhou Y., Wu D., Cui Q. H., Fu F. Y. and Wu L. L. (2012) Insulin decreases myocardial adiponectin receptor 1 expression via PI3K/Akt and FoxO1 pathway. Cardiovasc. Res. 93, 69-78.
13. Lu M., Wan M., Leavens K. F., Chu Q., Monks B. R., Fernandez S., Ahima R. S., Ueki K., Kahn C. R. and Birnbaum M. J. (2012) Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat. Med. 18, 388-395.
14. Rodgers J. T. and Puigserver P. (2007) Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc. Natl. Acad. Sci. U.S.A. 104, 12861-12866.
15. Adding L. C., Bannenberg G. L. and Gustafsson L. E. (2001) Basic experimental studies and clinical aspects of gadolinium salts and chelates. Cardiovasc. Drug Rev. 19, 41-56.
16. 3) on the appearance of macrophage populations and fibrogenesis in thioacetamide-induced rat hepatic lesions. J. Comp. Pathol. 133, 92-102.
17. Fricker S. P. (2006) The therapeutic application of lanthanides. Chem. Soc. Rev. 35, 524-533.
18. Fu L. J., Li J. X., Yang X. G. and Wang K. (2009) Gadolinium-promoted cell cycle progression with enhanced S-phase entry via activation of both ERK and PI3K signaling pathways in NIH 3T3 cells. J. Biol. Inorg. Chem. 14, 219-227.
19. Neyrinck A. M., Cani P. D., Dewulf E. M., De Backer F., Bindels L. B. and Delzenne N. M. (2009) Critical role of Kupffer cells in the management of diet-induced diabetes and obesity. Biochem. Biophys. Res. Commun. 385, 351-356.
20. Surwit R. S., Kuhn C. M., Cochrane C., McCubbin J. A. and Feinglos M. N. (1988) Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37, 1163-1167.
21. Burcelin R., Crivelli V., Dacosta A., Roy-Tirelli A. and Thorens B. (2002) Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. Am. J. Physiol. Endocrinol. Metab. 282, E834-E842.
22. U.S. Office of Science and Technology Policy (1985) Laboratory animal welfare; U.S. government principles for the utilization and care of vertebrate animals used in testing, research and training; notice. Fed. Regist. 50, 20864-20865.
23. Clark J. D., Gebhart G. F., Gonder J. C., Keeling M. E. and Kohn D. F. (1997) Special Report: The 1996 Guide for the Care and Use of Laboratory Animals. ILAR J. 38, 41-48.
24. Tsuneki H., Murata S., Anzawa Y., Soeda Y., Tokai E., Wada T., Kimura I., Yanagisawa M., Sakurai T. and Sasaoka T. (2008) Age-related insulin resistance in hypothalamus and peripheral tissues of orexin knockout mice. Diabetologia 51, 657-667.
25. Bian L., Hanson R. L., Ossowski V., Wiedrich K., Mason C. C., Traurig M., Muller Y. L., Kobes S., Knowler W. C., Baier L. J. and Bogardus C. (2010) Variants in ASK1 are associated with skeletal muscle ASK1 expression, in vivo insulin resistance, and type 2 diabetes in Pima Indians. Diabetes 59, 1276-1282.
26. Pei R., Zhang X., Xu S., Meng Z., Roggendorf M., Lu M. and Chen X. (2012) Regulation of hepatitis C virus replication and gene expression by the MAPK-ERK pathway. Virol. Sin. 27, 278-285.
27. Boden G., Chen X. and Stein T. P. (2001) Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus. Am. J. Physiol. Endocrinol. Metab. 280, E23-E30.
28. Nadler S. T., Stoehr J. P., Rabaglia M. E., Schueler K. L., Birnbaum M. J. and Attie A. D. (2001) Normal Akt/PKB with reduced PI3K activation in insulin-resistant mice. Am. J. Physiol. Endocrinol. Metab. 281, E1249-E1254.
29. Matsuzaki H., Daitoku H., Hatta M., Tanaka K. and Fukamizu A. (2003) Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc. Natl. Acad. Sci. U.S.A. 100, 11285-11290.
30. DeFronzo R. A. (1997) Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth. J. Med. 50, 191-197.
31. Novak S., Stapleton L. M., Litaker J. R. and Lawson K. A. (2003) A confirmatory factor analysis evaluation of the coronary heart disease risk factors of metabolic syndrome with emphasis on the insulin resistance factor. Diabetes Obes. Metab. 5, 388-396.